TIM
BMRN icon

Tortoise Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tortoise Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$217 – 385
2025
Q3 		$217 Sell
4
-4
-50% -$229 ﹤0.01% 1302
2025
Q2 		$440 Buy
+8
New +$471 ﹤0.01% 1105

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Tortoise Investment Management's BMRN Position: Q4 2025 in Review

Tortoise Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4 shares — an estimated $217 sold.

Tortoise Investment Management first reported a position in BMRN in Q2 2025 and held it in 2 quarters. The position peaked at $440 in Q2 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Tortoise Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tortoise Investment Management sold 4 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $217.
  • Tortoise Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Tortoise Investment Management's BioMarin Pharmaceuticals position peaked at $440 in Q2 2025.
  • 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.